Broadcrest, Universal Beteiligungs und Servicegesellschaft, Stephens Investment Management, and Pembroke Management have increased stakes in Bio-Techne Corp, whereas Massachusetts Financial Services, Ownership Capital, Summit Creek Advisors, Conestoga Capital Advisors, and HB Wealth Management have decreased their stakes. Bio-Techne has launched Simple Plex Ultra-Sensitive Assays on Ella Platform for femtogram-level detection of neurological biomarkers. Certain assets are hinting towards an upcoming recovery, despite the firm's lackluster earnings. The firm is set to host a conference call on February 4, 2026, to present Q2 FY2026 results. Bio-Techne's partnerships with Wyss Center Geneva and Oxford Nanopore Technologies aim to advance multiomics technology and accelerate genetics portfolio development respectively.
The company is profiting from AI with licensing AI-Designed NovoBody Duo Molecules from Monod Bio and a collaboration with Nucleai for AI-powered spatial biology workflow. It has shown progress on climate, innovation, and culture as also highlighted in its 2025 Sustainability Report. Despite Q4 earnings beating estimates and stronger organic growth, TECH stocks fell due to missed Q3 revenue estimates and lower gross margin at Q4. Bio-Techne continues to be a favored player in the biotech sector by analysts but there are concerns on valuation after recent analyst downgrade."
Bio-Techne Corp TECH News Analytics from Wed, 26 Mar 2025 07:00:00 GMT to Sat, 31 Jan 2026 18:44:02 GMT - Rating 6 - Innovation 7 - Information 9 - Rumor -1
